Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial
- 1 March 2015
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 182, 459-465
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trialAmerican Heart Journal, 2014
- Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptideEuropean Journal of Preventive Cardiology, 2013
- Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart diseaseJournal of Clinical Epidemiology, 2012
- Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective?Cardiology, 2011
- Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: A prognostic study within the CLARICOR TrialAtherosclerosis, 2011
- High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR TrialScandinavian Journal of Clinical and Laboratory Investigation, 2010
- Statin Treatment Prevents Increased Cardiovascular and All-Cause Mortality Associated With Clarithromycin in Patients With Stable Coronary Heart DiseaseJournal of Cardiovascular Pharmacology, 2010
- High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery diseaseEuropean Heart Journal, 2009
- Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart DiseaseCardiology, 2008
- Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trialBMJ, 2005